PROGRAMME SCHEDULE DAY-1: THURSDAY, 05TH SEPTEMBER, 2019 8:00 to 8:45AM: REGISTRATION 8:45 to 8:50AM 8:50 to 9:00AM 9:00 to 9:05AM 9:05 to 9:10AM 9:10 to 9:15AM Prayer Welcome and introductory remarks – Dr. J. V. Peter, Director / Dr. Anna Pulimood, Principal, CMC Address by Dr. Renu Swarup, Secretary, Department of Biotechnology (DBT), Govt. of India Address by Dr. Balram Bhargava, Secretary, Department of Health Research (DHR), Govt. of India & Director General, Indian Council of Medical Research (ICMR) Address by Dr. V. G. Somani, Drug Controller General (India), Central Drugs Standard Control Organisation (CDSCO), Govt. of India Session-1: IMMUNE CELL THERAPY Chair: Shubhada Chiplunkar 9:20 to 9:25AM Introduction to the session 9:25 to 9:55AM Developing ligand-based chimeric antigen receptors to target leukemic and bone marrow stem cells Trent Spencer Emory University School of Medicine, USA 9:55 to 10:25AM Translating indigenous CAR T cell therapy from lab to clinic Rahul Purwar Indian Institute of Technology Bombay, India 10:25 to 10:55AM Third party antigen specific T cells for treatment of virus infections after allogeneic stem cell transplant David Gottlieb Westmead Hospital Sydney, Australia 10:55 to 11:25AM Tea / Coffee Break Session-2: APPLICATIONS OF iPSC TECHNOLOGY Chair: Raghu Padinjat 11:25 to 11:30AM Introduction to the session 11:30 to 12:00PM International quality standards for clinical-grade induced pluripotent stem cells Stephen Sullivan Global Alliance for iPSC Therapies, UK 12:00 to 12:30PM Clinically compliant culture systems for the iPSC work flow Roland Leathers Thermo Fisher Scientific, Switzerland 12:30 to 1:00PM Application of iPSCs for understanding the molecular basis of neurological diseases Odity Mukherjee Institute for Stem Cell Science and Regenerative Medicine, India 1:00 to 2:00PM Lunch Session-3: TECHNOLOGY ADVANCES Chair: Rita Mulherkar 2:00 to 2:05PM Introduction to the session 2:05 to 2:35PM Development of AAV vectors capable of evading neutralizing antibodies and dampening the host humoral immune response Arun Srivastava University of Florida College of Medicine, USA 2:35 to 3:05PM CRISPR 2.0: Tackling the specificity problem Debojyoti Chakraborty CSIR-Institute of Genomics and Integrative Biology, India 3:05 to 3:35PM Vector manufacturing for bench vs bedside: Bridging the chasm between preclinical and clinical manufacturing strategies Trent Spencer Emory University School of Medicine, USA 3:35 to 4:35PM Tea / Coffee Break with Poster Session Session-4: MANUFACTURING AND REGULATORY ASPECTS IN CELL AND GENE THERAPY Chair: Thangarajan Rajkumar 4:35 to 4:40PM Introduction to the session 4:40 to 5:10PM Good manufacturing practice for pluripotent stem cell for clinical grade application Mahendra Rao Institute for Stem Cell Science and Regenerative Medicine, India 5:10 to 5:40PM Quality control for hPSC lines and hPSC-based products Glyn Stacey International Stem Cell Banking Initiative, UK 5:40 to 6:10PM Manufacturing of advanced therapy medicinal products in a European academic setting Pontus Blomberg Karolinska Institutet and Karolinska University Hospital, Sweden KEY NOTE ADDRESS Chair: Alok Srivastava 6:10 to 6:15PM Introduction 6:15 to 7:15PM Evolution of T- cell therapy for infections David Gottlieb Westmead Hospital Sydney, Australia 7:15PM onwards Dinner DAY-2: FRIDAY, 06TH SEPTEMBER, 2019 Session-5: GENE EDITING Chair: R V Shaji 8:00 to 8:05AM Introduction to the session 8:05 to 8:35AM High-level Cas9-mediated correction of the sickle mutation in human hematopoietic stem cells David Martin Children’s Hospital Oakland Research Institute, USA 8:35 to 9:05AM Rewinding the internal clock of hemoglobin synthesis in adult stem cells Sivaprakash Ramalingam CSIR-Institute of Genomics and Integrative Biology, India 9:05 to 9:35AM Therapeutic Gene editing at the β-globin locus Sowmya Pattabhi Seattle Children’s Research Institute, USA 9:35 to 10:05AM Crispr-Cas9 mediated HPFH like mutations for fetal hemoglobin reactivation Saravanabhavan Thangavel Centre for Stem Cell Research, India 10:05 to 11:05AM Tea / Coffee Break with Poster Session Session-6: GENE THERAPY Chair: Alok Srivastava 11:05 to 11:10AM Introduction to the session 11:10 to 11:40AM Emerging roles of transgene mutations in gene therapy products for hemophilia Christopher Doering Emory University School of Medicine, USA 11:40 to 12:10PM The role of miRNA17-92 cluster in AAV vector-mediated transgene expression Arun Srivastava University of Florida College of Medicine, USA 12:10 to 12:40PM Next-generation gene therapy and gene editing for muscle disorders Thierry VandenDriessche Free University of Brussels & University of Leuven, Belgium 12:40 to 1:10PM Targeting erythroid specific BCL11A enhancer in hematopoietic stem and progenitor cells for the therapeutic induction of fetal hemoglobin Mohankumar Murugesan Centre for Stem Cell Research, India 1:10 to 2:10PM Lunch Session-7: CELL THERAPY IN OCULAR DISORDERS Chair: Arkasubhra Ghosh 2:10 to 2:15PM Introduction to the session 2:15 to 2:45PM Limbal derived stem cells in corneal and limbal wound healing Vivek Singh L.V. Prasad Eye Institute, India 2:45 to 3:15PM Cell Therapy of corneal diseases with umbilical mesenchymal stem / stromal cells Winston W-Y Kao University of Cincinnati, USA 3:15 to 3:45PM Retinal cell replacement in macular degeneration: A pluripotent stem cell-based approach Rajarshi Pal Eyestem Research Private Limited, India 3:45 to 4:00PM Conclusion remarks